Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

NCT00042302 is registered in ClinicalTrials.gov with QLT Inc. as lead sponsor.

NCT NCT00042302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00042302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
QLT Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2002
Completion date
July 31, 2003
Enrollment
540
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage iiib non-small cell lung cancer, stage iv non-small cell lung cancer